[
  {
    "vignette_index": 1146,
    "input": "Subacute cutaneous lupus erythematosus END",
    "output": "THINKING: Use systematic clinical reasoning to develop a treatment approach:  STEP 1 - DIAGNOSIS CONFIRMATION & SEVERITY ASSESSMENT: Let me first confirm the diagnosis and assess severity/urgency. - Primary diagnosis confidence: Moderate to high, given the characteristic skin lesions and oral sores suggest subacute cutaneous lupus erythematosus (SCLE), though her presentation overlaps with other autoimmune conditions. - Severity classification: Moderate, due to widespread skin involvement, pruritus, and oral sores impacting quality of life, but no systemic symptoms or organ-threatening features noted. - Urgency level: Routine care needed, with prompt initiation of treatment to prevent progression and improve symptoms. - Differential considerations still requiring monitoring: Systemic lupus erythematosus (SLE) with subclinical systemic involvement, lichenoid reactions, or other dermatoses.  STEP 2 - EVIDENCE-BASED TREATMENT SELECTION: Now I'll select treatments based on current clinical guidelines. - First-line treatment per guidelines: Topical corticosteroids combined with sun protection and systemic antimalarials such as hydroxychloroquine. - Supporting evidence: Antimalarials are effective for SCLE, improving skin lesions and oral ulcers, and are generally well tolerated. - Patient-specific considerations: Her pruritus, oral sores, and diffuse skin lesions favor systemic therapy; previous lack of systemic treatment suggests starting with established options. - Contraindications or cautions: Screen for G6PD deficiency before initiating hydroxychloroquine; monitor for retinal toxicity with long-term use.  STEP 3 - PHARMACOLOGICAL INTERVENTIONS: If medications are appropriate, I'll select based on efficacy and safety. - Primary medication choice: Hydroxychloroquine 200 mg twice daily. - Rationale for selection: Evidence supports its efficacy in SCLE, with a favorable safety profile; topical steroids for localized skin lesions. - Expected timeline for improvement: Skin and oral ulcer improvement typically seen within 6-12 weeks. - Key side effects to monitor: Retinal toxicity \u2013 perform baseline and annual ophthalmological exams; GI upset, rash, or neuropsychiatric symptoms. - Alternative medications if first-line fails: Methotrexate or azathioprine for refractory cases; systemic corticosteroids as needed for flares.  STEP 4 - NON-PHARMACOLOGICAL INTERVENTIONS: I'll include lifestyle and behavioral interventions that enhance outcomes. - Primary non-drug interventions: Sun avoidance, broad-spectrum sun protection, and skin hydration. - Patient education priorities: Importance of medication adherence, sun protection measures, and recognizing signs of systemic involvement. - Lifestyle modifications: Avoid excessive sun exposure; use protective clothing and broad-spectrum sunscreens. - Behavioral interventions: Techniques to manage itch and stress, possibly including relaxation training or counseling.  STEP 5 - MONITORING & FOLLOW-UP STRATEGY: I'll establish appropriate monitoring and follow-up care. - Follow-up timeline: Reassess at 6-8 weeks after starting hydroxychloroquine; sooner if symptoms worsen. - Monitoring parameters: Skin lesion status, oral ulcer severity, medication adherence, and side effects; baseline and annual eye exams. - Red flag symptoms: New joint pains, chest pain, persistent fevers, or neuropsychiatric changes \u2013 warrant urgent evaluation. - Treatment response assessment: Symptom reduction, improved skin appearance, and healing of oral sores.  STEP 6 - PATIENT COMMUNICATION STRATEGY: Given the patient's behavioral type (information_withholder), how should I communicate this plan? - Communication approach: Use clear, simple language; verify understanding; provide written summaries. - Addressing patient concerns: Emphasize that the treatment aims to control symptoms and prevent complications; reassure about safety and monitoring. - Adherence strategies: Schedule regular follow-ups; involve her in decision-making; address concerns about medication side effects. - Family involvement: With her consent, involve family members in education and support.  STEP 7 - COORDINATION & REFERRALS: What additional care coordination is needed? - Specialist referrals needed: Dermatology for ongoing skin management and ophthalmology for eye monitoring. - Other healthcare team members: Rheumatology if systemic features develop or to evaluate for systemic lupus. - Community resources: Support groups for autoimmune skin conditions; educational materials. - Insurance/cost considerations: Ensure medication coverage; discuss generic options if needed for affordability.\nANSWER: Based on the diagnosis of subacute cutaneous lupus erythematosus, I recommend a comprehensive treatment approach that combines evidence-based medical management with patient-centered care strategies. The treatment plan includes initiating hydroxychloroquine 200 mg twice daily alongside topical corticosteroids applied to affected skin, emphasizing sun avoidance and protective measures. This approach aims to reduce skin lesions, oral ulcers, and pruritus while preventing systemic progression. Regular ophthalmologic monitoring is essential due to potential retinal toxicity, and follow-up should occur every 6-8 weeks initially to assess response and adjust therapy as needed. Patient education will focus on medication adherence, sun protection, and recognizing warning signs. Coordination with dermatology and ophthalmology specialists is vital. This integrated plan seeks to optimize disease control, improve quality of life, and prevent complications while respecting her individual circumstances.  IMPLEMENTATION GUIDANCE: - Immediate actions (today): Educate the patient about her condition and treatment plan; start hydroxychloroquine after baseline eye exam; prescribe topical corticosteroids and sun protection measures. - Short-term goals (1-4 weeks): Confirm medication adherence; assess side effects; monitor for initial improvement. - Long-term objectives (3-6 months): Achieve sustained skin and oral lesion remission; prevent systemic involvement; monitor for medication toxicity. - Patient handout summary: Key points on medication use, sun safety, symptom monitoring, and follow-up schedule.",
    "gold_diagnosis": "Follicular lichen planus"
  }
]